

## ORIGINAL

# Treatment with DHA/EPA ameliorates atopic dermatitis-like skin disease by blocking LTB4 production

Shinya Yoshida<sup>1</sup>, Koji Yasutomo<sup>1</sup>, and Toshiyuki Watanabe<sup>2</sup>

<sup>1</sup>Department of Immunology & Parasitology, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan, <sup>2</sup>Department of Pediatrics, Takamatsu City Hospital, Takamatsu, Kagawa 760-8351, Japan

**Abstract :** Atopic dermatitis (AD) is caused by both dysregulated immune responses and an impaired skin barrier. Although leukotriene B4 (LTB4) is involved in tissue inflammation that occurs in several disorders, including AD, therapeutic strategies based on LTB4 inhibition have not been explored. Here we demonstrate that progression of an AD-like skin disease in NC/Nga mice is inhibited when docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) is administered together with FK506. Treatment with DHA/EPA and FK506 decreases the clinical score of dermatitis in NC/Nga mice and lowers local LTB4 concentrations. The treatment also suppressed the infiltration of T cells, B cells, eosinophils and neutrophils, and promoted reduced serum IgE levels. Secretion of IL-13 and IL-17A in CD4<sup>+</sup> T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone. The inhibition of disease progression induced by DHA/EPA was reversed by local injection of LTB4, suggesting that the therapeutic effect of DHA/EPA is LTB4-dependent. Our results demonstrate that treatment of AD with DHA/EPA is effective for allergic skin inflammation and acts by suppressing LTB4 production. *J. Med. Invest.* 63 : 187-191, August, 2016

**Keywords :** docosahexaenoic acid, eicosapentaenoic acid, atopic dermatitis, leukotriene B4

## INTRODUCTION

Atopic dermatitis (AD) is caused by a dysregulated immune response and skin barrier disruption (1-4). AD patients generally have elevated IgE as well as enhanced differentiation of Th1, Th2, and Th17 cells (2, 5). Moreover, increased numbers of Th17 cells are associated with AD severity (6). As for skin barrier disruptions, loss-of-function mutations of filaggrin are associated with AD (7, 8) and filaggrin-deficient mice develop skin inflammation that is accompanied by increased Th17 differentiation (3, 9). Therefore, depending on disease severity, AD treatment can involve a combination of oral anti-histamines, anti-leukotrienes and ointments that include steroids, FK506 or NSAIDs (1). However, the long-term use of steroids or FK506 may cause severe side effects, which is problematic for younger patients in particular.

Several studies have shown that  $\omega$ 3 free fatty acid (FFA) intake through supplementation or foods can suppress the progression of inflammatory diseases (10, 11). These FFAs could suppress inflammatory responses by inhibiting production of IL-6 as well as prostaglandins and leukotrienes (12) that participate in skin inflammation by activating T cells and neutrophils (13). Moreover, the application of the leukotriene B4 (LTB4) receptor antagonist ONO-4057 inhibited spontaneous itch phenotypes in NC mice that are an animal model of AD (14). This finding suggests that LTB4 plays an important role in AD progression.

We developed an ointment containing the FFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) as a topical AD therapeutic and tested its efficacy in suppressing symptoms in AD patients (15). To determine the molecular mechanism by which this ointment alleviates symptoms, we evaluated the therapeutic

efficacy of DHA/EPA on AD-like disease in NC/Nga mice. We found that DHA/EPA administered together with FK506 can ameliorate AD by suppressing LTB4 production. These data demonstrate the molecular basis for the therapeutic efficacy of DHA/EPA on AD and suggest that DHA/EPA may be a useful component in ointments used to treat AD.

## MATERIAL AND METHODS

### Mice

NC/Nga mice (8-10 weeks old) were purchased from Charles River (Yokohama, Japan) and housed in the Animal Research Center of the University of Tokushima under specific pathogen-free conditions. All mice were housed under specific pathogen-free conditions. The animal studies in this manuscript was approved by the Committee on the Ethics of Animal Experiments of Tokushima University and the care and use of animals complied with institutional guidelines. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

### DHA/EPA

Cod liver oil containing DHA 20% and EPA 10% were provided by NOF Corporation (Tokyo, Japan).

### Dermatitis model

The hair in the rostral region on the backs of the mice was removed with a depilatory cream. The mice were then challenged with an ointment that included a *Dermatophagoides farinae* body extract (Biosta AD) (Biosfir, Kobe, Japan) twice weekly for 3 weeks. The first day for the challenge was designated as day 0. Before the first challenge, the skin barrier was disrupted by treatment with a 4% SDS solution. The FK506 (0.3 mg) and/or DHA/EPA (Cod liver oil : 100 mg, EPA 8.3%, DHA 14.6%) ointment was applied at the area where Biosta AD was painted on days 4, 8, 12, 16, and 20.

Received for publication January 8, 2016 ; accepted February 25, 2016.

Address correspondence and reprint requests to Toshiyuki Watanabe, M.D., Ph.D. Department of Pediatrics, Takamatsu City Hospital, Takamatsu 760-8351, Kagawa, Japan, and Koji Yasutomo, M.D., Ph.D. Department of Immunology & Parasitology, Graduate School of Medicine, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan and Fax : +81-88-633-7114.

#### Purification of cells from skin tissue and flow cytometry analysis

Skin tissue was digested with 2.5 mg/mL dispase II (Roche), 3 mg/ml collagenase (Worthington Biochemicals, USA) and 5  $\mu$ g DNase (Roche) for 120 min at 37°C. After removal of cell debris, cells were stained with APC-conjugated anti-CD3, FITC-conjugated anti-B220, PE-Cy7-conjugated Gr1, APC-Cy7-conjugated CD11b, or PE-conjugated Siglec-F antibody. Flow cytometry was performed on a FCAS CantoII flow cytometer (Becton Dickinson, Mountain View, CA).

#### Cell culture

CD4<sup>+</sup> T cells were isolated from lymph nodes by incubating cells with anti-B220, anti-CD32/16, anti-CD11b, and anti-CD8 mAbs followed by incubation with anti-rat IgG-coated Dynabeads (Thermo Fisher Scientific Inc., USA). Purified CD4<sup>+</sup> T cells were stimulated with irradiated spleen cells in the presence of anti-CD3 mAb (1  $\mu$ g/ml) for 2 days.

#### Measurement of leukotriene levels

A section of skin (2 cm in diameter) was removed, minced with scissors and placed in ethanol containing indomethacin and zileuton. After sample homogenization and subsequent centrifugation for 5 min at 600 $\times$ g and 4°C, the supernatant was mixed with water and applied to a C18 Sep-Pak cartridge (Waters, Milford, MA, USA) equilibrated with methanol. After washing the cartridge with hexane and then water, lipids were eluted with ethanol. The ethanol was evaporated, with the remaining residue suspended in an enzyme immunoassay buffer included with a LTB<sub>4</sub> ELISA assay kit (Cayman Chemical, Ann Arbor, MI, USA). The protein concentration was measured and the amount of LTB<sub>4</sub> was normalized relative to that of the overall protein.

#### ELISA

IL-13, IFN- $\gamma$ , IL-17A, and IL-22 levels in culture supernatants were measured using an ELISA kit (R&D Systems, Minneapolis, MN). Serum from mice or standard IgG1, IgM, IgG2b or IgE (Southern Biotech, AL, USA) were serially diluted with PBS to

coat a 96 well plate overnight at 4°C. After washing with PBS/0.1% Tween 20, alkaline phosphatase-conjugated goat anti-mouse IgG1, IgM, IgG2b, or IgE (Southern Biotech, AL, USA) were added and incubated at room temperature for 2 hours. After washing wells with PBS/0.1% Tween 20, alkaline phosphatase activity was determined using 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich, MO, USA) as the substrate.

#### Scoring of skin lesions

The extent of (1) erythema/hemorrhage, (2) scarring/dryness, (3) edema, and (4) excoriation/erosion was scored as 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total skin score was defined as the sum of the individual scores  $\pm$  SD.

#### Histology

Skin tissue samples were fixed in 10% formalin, embedded in paraffin, and sectioned. Tissue sections were stained with hematoxylin and eosin.


#### Statistical analysis

The distributed data from interval scales were analyzed with Student's *t*-test; a *p* value of less than 0.05 was considered statistically significant.

## RESULTS

#### DHA/EPA attenuate atopic dermatitis-like diseases

We sought to analyze the effect of DHA/EPA on atopic-dermatitis like diseases (AD) in NC/Nga mice, an animal model of AD. AD is induced in these mice by painting an ointment containing *Dermatophagoides farinae* body extract on their backs. We applied DHA/EPA or FK506 alone or DHA/EPA with FK506 to treat the AD. Treatment with DHA alone did not ameliorate AD as evaluated by clinical score and histology (Fig. 1a and b). Meanwhile, treatment with FK506 ameliorated AD symptoms, and treatment with both FK506 and DHA/EPA further improved the clinical scores and histology (Fig. 1a and b). These data demonstrate that DHA/EPA



**Figure 1.** DHA/EPA attenuates skin inflammation

AD was induced by painting an ointment that contained *Dermatophagoides farinae* body extract onto the dorsal skin of NC/Nga mice. We applied DHA/EPA or FK506 or DHA/EPA with FK506 on the dorsal skin and evaluated the (a) clinical score and (b) skin histology by HE staining 30 days after initial induction. The data are shown as mean  $\pm$  S.D. (n=8 in each experiment). \*\*indicates statistical difference (*p* < 0.01). The data are representative of six independent experiments.

EPA can suppress AD when used with FK506.

#### DHA/EPA decreased the number of T cells that infiltrate the skin

We next evaluated the number of immune-related cells infiltrating the skin after treatment. Twenty days after initial AD induction, skin tissue samples were taken and digested with collagenase and dispase. The number of T cells (CD3<sup>+</sup>), B cells (IgM<sup>+</sup>B220<sup>+</sup>), neutrophils (CD11b<sup>+</sup>Gr1<sup>+</sup>), and eosinophils (CD11b<sup>+</sup>SiglecF<sup>+</sup>) in these tissue samples were counted (Fig. 2). Treatment with FK506 did not affect cell numbers of any types of cells. In contrast, treatment with FK506 and DHA/EPA decreased the number of T cells, neutrophils and eosinophils (Fig. 2). These data show that DHA/EPA treatment could decrease the infiltration of T cells, neutrophils, and eosinophils in the skin.

#### DHA/EPA treatment decreases serum IgE and production of IL-13 and IL-17A by CD4<sup>+</sup> T cells

Given that DHA/EPA affects T cell numbers, we assessed serum immunoglobulin levels after DHA/EPA treatment (Fig. 3a). DHA/EPA together with FK506 decreased the amount of IgE but not levels of IgM, IgG1, and IgG2b. We also compared cytokine secretion from CD4<sup>+</sup> T cells in mice treated with FK506 alone and FK506 plus DHA/EPA. The CD4<sup>+</sup> T cells were purified from fluid drained from lymph nodes and stimulated with anti-CD3 mAb for 2 days. IL-13, IL-22, IL-17A, and IFN- $\gamma$  expression was upregulated by treatment with *Dermatophagoides farinae* body extract (Fig. 3b). Treatment with FK506 and DHA/EPA decreased IL-13 and IL-17A secretion while FK506 alone did not affect the levels of any of the cytokines tested. Together these results indicated that DHA/EPA treatment decreases the secretion of IL-13 and IL-17A from CD4<sup>+</sup> T cells.

#### DHA/EPA treatment decreases LTB4 production

DHA/EPA have the capacity to suppress leukotriene production (16). We evaluated levels of the leukotriene LTB4 in the skin after DHA/EPA treatment. Dorsal skin tissue samples were digested and levels of the LTB4 protein were evaluated. FK506 treatment did not affect the amount of LTB4 in the skin, while FK506 with DHA/EPA significantly decreased LTB4 levels (Fig. 4a), indicating that DHA treatment affects LTB4 production.

To evaluate whether inhibition of LTB4 production contributes

to the suppression of AD by DHA/EPA, we injected LTB4 into the skin of DHA/EPA-treated mice. LTB4 injection inhibited the effect of DHA/EPA ointment therapy (Fig. 4b), suggesting that DHA/EPA-mediated suppression of AD is attributable to the suppression of LTB4 production.

## DISCUSSION

Bioactive lipids such as leukotrienes, prostaglandin, and eicosanoids are generated from arachidonic acid by 5-lipoxygenase and cyclooxygenase (17, 18). Leukotrienes and prostaglandins are involved in a variety of inflammatory diseases, including skin inflammation (17, 19). Based on our earlier finding that DHA could suppress symptoms in AD patients, here we used a mouse model of AD to assess whether an ointment containing DHA/EPA had therapeutic effects and also to determine the mechanisms by which DHA acts (15). Treatment with DHA/EPA alone had no effect on AD pathology, but treatment with both FK506 and DHA had strong therapeutic potential in the mouse model of AD. Furthermore, the effect of DHA/EPA was dependent on inhibition of LTB4 production. These data suggest the DHA may suppress symptoms of AD by inhibiting the production of key inflammatory eicosanoids.

Previous studies have suggested that the effect of FFA on inhibiting inflammation is attributable to changes in the fatty acid composition of cellular phospholipids, since FFAs rather than arachidonic acid can incorporate into cell membranes (20). Because FFAs are poor substrates for 5-lipoxygenase and cyclooxygenase, FFA incorporation into cell membranes could in turn suppress the production of eicosanoid mediators (16). The inhibition of LTB4 production by DHA/EPA treatment in our study also suggested the inhibitory effect of DHA/EPA on arachidonic acid. Alternatively, DHA and other FFAs could activate the fatty acid receptor GPR120 on cell surfaces, which may subsequently inhibit phosphorylation of the transforming growth factor  $\beta$ -activated kinase 1 (TAK1) that participates in the NF- $\kappa$ B and MAPK signaling pathways (21). Given that inhibition of TAK1 by RNAi suppresses Th1 and Th17 differentiation by targeting myeloid cells (22), future studies on the effect of DHA on TAK1 phosphorylation levels *in vivo* would be important to determine if TAK1 is associated with DHA/EPA-mediated suppression of AD pathology.






Figure 2. DHA/EPA treatment decreases T cell and eosinophil numbers in skin tissue

Dorsal skin tissue from NC/Nga mice treated with DHA/EPA, FK506 or DHA/EPA with FK506 (20 days after initial induction) was digested by collagenase and dispase. The cell numbers were then counted and the cells were stained with antibodies against CD3, IgM, B220, CD11b, Gr1 or SiglecF. The number of T cells (CD3<sup>+</sup>), B cells (IgM<sup>+</sup>B220<sup>+</sup>), neutrophils (CD11b<sup>+</sup>Gr1<sup>+</sup>), and eosinophils (CD11b<sup>+</sup>SiglecF<sup>+</sup>) are expressed as a total cell number/g of skin tissue. The data are shown as mean  $\pm$  S.D. (n = 8 in each experiment). \*\*indicates statistical difference ( $p < 0.01$ ). The data are representative of five independent experiments.



**Figure 3.** DHA/EPA treatment decreases IgE and cytokines expression from T cells (a) AD was induced by painting an ointment containing *Dermatophagoides farinae* body extract onto the dorsal skin of NC/Nga mice. We painted FK506 alone or DHA/EPA with FK506 on the dorsal skin of mice and evaluated serum IgE, IgG1, IgG2, and IgM levels 30 days after initial induction. The data are shown as mean ± S.D. (n=8 in each experiment). \*indicates statistical difference ( $p < 0.05$ ). (b) We applied FK506 alone or DHA with FK506 on the dorsal skin of mice treated with Biosta. Thirteen days after initial Biosta treatment, CD4<sup>+</sup> T cells were purified and stimulated with plate-coated anti-CD3 mAb for 2 days. Levels of IL-13, IL-17A, IL-22, and IFN-γ in the supernatant were evaluated by ELISA. The data are shown as mean ± S.D. (n=8 in each experiment). \*indicates statistical difference ( $p < 0.05$ ). The data are representative of six independent experiments.



**Figure 4.** The therapeutic effect of DHA/EPA is attributable to the suppression of LTB4 AD is induced by painting an ointment containing *Dermatophagoides farinae* body extract onto the dorsal skin of NC/Nga mice. (a) We applied DHA/EPA or FK506 alone or DHA with FK506 onto the dorsal skin and collected dorsal skin tissue 20 days after initial induction. LTB4 protein levels were measured by ELISA. The data are shown as mean ± S.D. (n=8 in each experiment). \*indicates statistical difference ( $p < 0.05$ ). (b) We applied FK506 alone or DHA/EPA with FK506 onto the dorsal skin and then injected LTB4 at 10 different sites on the dorsal skin (2 pg/site). The clinical score was evaluated. The data are shown as mean ± S.D. (n=5 in each experiment). \*indicates statistical difference ( $p < 0.05$ ). The data are representative of three independent experiments.

The therapeutic efficacy of DHA/EPA was observed when it was administered together with FK506 while DHA/EPA alone failed to ameliorate AD pathology. FK506 is a potent T cell suppressive drug that makes a complex with FKBP resulting in inhibiting dephosphorylation of NFAT (23). This finding may have two possible explanations : i) treatment with DHA/EPA alone may be

able to suppress AD, but its effect would be too weak to ameliorate AD pathology in this AD model ; or ii) Suppression of T cell responses by FK506 is needed in order for DHA/EPA to exert its effects in this model. These AD model mice exhibited a scratching behavior that is related to the progression of AD pathology. FK506 treatment suppressed this scratching behavior (24), and thus this

compound might be required for DHA/EPA to produce a therapeutic effect on AD. In contrast, in AD patients DHA/EPA alone has treatment efficacy, which might be attributable to the lower incidence of scratching in humans relative to NC/Nga mice.

In conclusion, DHA/EPA could suppress AD pathology by inhibiting LTB<sub>4</sub> production in an AD mouse model. Although the molecular mechanism by which DHA/EPA suppresses LTB<sub>4</sub> in this AD model awaits further clarification, these data suggest that ointments including DHA/EPA would be a beneficial treatment for AD patients when DHA/EPA is administered together with FK 506.

#### CONFLICT OF INTERESTS-DISCLOSURE

All authors do not have any conflict of interest.

#### ACKNOWLEDGEMENTS

We thank Mrs. Miyamoto and Kinouchi for their editorial and technical assistance. We also thank Life Science Products Division, NOF Corporation, NAIGAI YAKUHIIN CO.,LTD for providing us DHA/EPA samples.

#### REFERENCES

1. Novak N, Leung DY : Advances in atopic dermatitis. *Current opinion in immunology* 23 : 778-783, 2011
2. Wu LC, Scheerens H : Targeting IgE production in mice and humans. *Current opinion in immunology* 31 : 8-15, 2014
3. Thyssen JP, Kezic S : Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. *The Journal of allergy and clinical immunology* 134 : 792-799, 2014
4. Peng W, Novak N : Recent developments in atopic dermatitis. *Current opinion in allergy and clinical immunology* 14 : 417-422, 2014
5. Lipozencic J, Pastar Z, Kulisic SM, Pavic I : Immunologic aspects of atopic dermatitis. *Acta dermatovenerologica Croatica : ADC* 17 : 226-234, 2009
6. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y : Possible pathogenic role of Th17 cells for atopic dermatitis. *The Journal of investigative dermatology* 128 : 2625-2630, 2008
7. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, Houate BEI, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH : Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nature genetics* 38 : 441-446, 2006
8. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH : Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nature genetics* 38 : 337-342, 2006
9. Oyoshi MK, Murphy GF, Geha RS : Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. *The Journal of allergy and clinical immunology* 124 : 485-493, 493 e481, 2009
10. Talukdar S, Olefsky JM, Osborn O : Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. *Trends in pharmacological sciences* 32 : 543-550, 2011
11. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Hwang BS, Glaser R : Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults : a randomized controlled trial. *Brain, behavior, and immunity* 26 : 988-995, 2012
12. Mullen A, Loscher CE, Roche HM : Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages. *The Journal of nutritional biochemistry* 21 : 444-450, 2010
13. Oyoshi MK, He R, Li Y, Mondal S, Yoon J, Afshar R, Chen M, Lee DM, Luo HR, Luster AD, Cho JS, Miller LS, Larson A, Murphy GF, Geha RS : Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. *Immunity* 37 : 747-758, 2012
14. Andoh T, Haza S, Saito A, Kuraishi Y : Involvement of leukotriene B4 in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions. *Experimental dermatology* 20 : 894-898, 2011
15. Watanabe T, Kuroda Y : The effect of a newly developed ointment containing eicosapentaenoic acid and docosahexaenoic acid in the treatment of atopic dermatitis. *The journal of medical investigation : JMI* 46 : 173-177, 1999
16. Stulnig TM : Immunomodulation by polyunsaturated fatty acids : mechanisms and effects. *International archives of allergy and immunology* 132 : 310-321, 2003
17. Kuhn H, Banthiya S, van Leyen K : Mammalian lipoxygenases and their biological relevance. *Biochimica et biophysica acta* 1851 : 308-330, 2015
18. Capra V, Rovati GE, Mangano P, Buccellati C, Murphy RC, Sala A : Transcellular biosynthesis of eicosanoid lipid mediators. *Biochimica et biophysica acta* 1851 : 377-382, 2015
19. Lone AM, Tasken K : Proinflammatory and immunoregulatory roles of eicosanoids in T cells. *Frontiers in immunology* 4 : 130, 2013
20. Healy DA, Wallace FA, Miles EA, Calder PC, Newsholm P : Effect of low-to-moderate amounts of dietary fish oil on neutrophil lipid composition and function. *Lipids* 35 : 763-768, 2000
21. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM : GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell* 142 : 687-698, 2010
22. Courties G, Seiffart V, Presumey J, Escrivou V, Scherman D, Zwerina J, Ruiz G, Zietara N, Jablonska J, Weiss S, Hoffmann A, Jorgensen C, Apparailly F, Gross G : In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. *Blood* 116 : 3505-3516, 2010
23. Lofgren S, Krol A : New therapies in pediatric dermatology. *Curr Opin Pediatr* 23 : 399-402, 2011
24. Takano N, Arai I, Hashimoto Y, Kurachi M : Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice. *European journal of pharmacology* 495 : 159-165, 2004